Is Fecal Leukocyte Test a good predictor of Clostridium difficile associated diarrhea?

Savio Reddymasu*, Ankur Sheth and Daniel E Banks

Address: Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA
Email: Savio Reddymasu* - saviocharan@gmail.com; Ankur Sheth - drankursheth@yahoo.com; Daniel E Banks - dbanks3@lsuhsc.edu
* Corresponding author

Abstract

Background: Fecal leukocyte test (FLT) is widely used to screen for invasive diarrheas including C. difficile associated diarrhea (CDAD), which account for more than 25% of all antibiotic associated diarrhea.

Method: 263 stool samples from patients with suspected CDAD were studied simultaneously for fecal leukocyte test (FLT) and Clostridium difficile toxin assay (CDTA). FLT was performed by the Giemsa technique and CDTA was performed by enzyme immuno assay (EIA).

Results: Sensitivity, specificity, positive predictive value and negative predictive value of FLT as compared to CDTA were 30%, 74.9%, 13.2% and 89.3% respectively.

Conclusion: Considering the poor sensitivity of FLT, and the comparable cost and time of obtaining a CDTA at our institution, we conclude that FLT is not a good screening test for CDAD. Possible reasons for FLT being a poor predictor of CDTA are discussed.

Introduction

Willmore and Shearman[1] first described the fecal leukocyte stain in 1918 followed by its clinical use for diagnosis of bacterial diarrhea in 1972 by Harris et al [2]. Today fecal leukocyte testing (FLT) is widely used to screen for inflammatory diarrhea including C. difficile diarrhea, which account for more than 25% of all antibiotic associated diarrhea. Laboratory diagnosis of C. difficile associated diarrhea (CDAD) is based on the detection of C. difficile toxins in stool samples by a cell culture cytotoxicity assay or enzyme immunoassay. We evaluated FLT within an inpatient cohort, defining the test’s sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for patients with CDAD.

Materials and methods

After obtaining approval from the institutional review board at Louisiana State University Health Sciences Center, Shreveport, a retrospective review of laboratory data was done on 263 inpatients whose stool samples were simultaneously submitted for FLT and C. difficile toxin assay (CDTA). Specimens were submitted between January 2001 and June 2004.

FLT was performed on fresh stool specimens. Samples are obtained in a clean dry container. Stool specimens are applied as a thin smear on a slide using a cotton swab. After the slides are air dried, they are smeared with Wright stain and examined under the microscope for white blood cells (WBC). Criteria for positive FLT are > 1 WBC/high power field. The cost of obtaining a FLT is about $30.
Time of availability of the test is approximately one hour after submission of the stool specimen. Specimens were processed in the same laboratory, but likely by different technicians.

CDTA was done using Premier™ Toxins A&B (PT A&B). PT A&B is an EIA for the direct detection of *C. difficile* toxin A and toxin B. CDAD was defined as diarrhea with a positive CDTA. The cost of obtaining CDTA is about $30. Time of availability is approximately 45 minutes after submission of the specimen.

**Results**

Of the 263 stool samples tested at the same time for FLT and CDTA, 68 were positive for FLT and 30 were positive for CDTA (Table 1). The sensitivity and specificity of FLT as compared to CDTA was 30 % and 74.9 % respectively. The PPV and NPV of FLT was 13.2 % and 89.3 % respectively for CDTA. 70% of all stool specimens positive for CDTA had a negative FLT. Prevalence of a positive CDTA was 11.4%.

**Discussion**

*Clostridium difficile* (*C. difficile*) is the commonest cause of nosocomial diarrhea associated with significant morbidity and health care costs.[3,4] Despite being perceived as a common cause of antibiotic associated diarrhea, *C. difficile* associated diarrhea (CDAD) is often difficult to diagnose.[3] Enzyme immunoassay (EIA) against *C. difficile* toxin A and/or toxin B in stool specimens is currently the acceptable method of diagnosing *C. difficile* diarrhea.[5-7] Since *C. difficile* is considered to be a type of invasive diarrhea, fecal leukocyte test (FLT), that has been proposed by Harris et al [2] as a rapid test to differentiate invasive versus non-invasive diarrhea [2,8] might be useful as a predictor of *C. difficile* diarrhea.

There is conflicting evidence regarding the use of FLT as a screening test for CDAD. While the studies done by Savola et al [9], Mark et al [10], Manabe et al [11] and Shanholtzer et al [12] concluded FLT as a poor predictor of CDAD; studies done by Bartlett et al [13] and Fekety et al [14] proposed that FLT might be a useful predictor in CDAD. The results of our study reinforce the fact that FLT is a poor predictor of CDAD; because 70% of stool specimens positive for *C. difficile* toxin are negative for fecal leukocyte. There is no significant time or cost savings by obtaining a FLT, as opposed to CDTA in patients with suspected CDAD.

Poor predictability of CDAD with a FLT can partially be explained by inter-observer variability in interpreting fecal leukocytes under microscopy. False negative results could also be due to degeneration of fecal leukocytes secondary to delay in processing stool specimens. This is reinforced by the fact that objective tests to detect fecal leukocytes like the fecal lactoferrin [15-18] or the fecal leukocyte esterase test [19] are better indicators of fecal leukocytes than the FLT. Low PPV can also be explained by the fact that EIA for toxin detection is less sensitive compared to the neutralizing tissue culture cytotoxicity assay for CDAD.

Considering the poor sensitivity and comparable cost and promptness with *C. difficile* toxins assay in our institution, we conclude that FLT is not a good screening test for CDAD in inpatients.

**Financial disclosure**

None

**Competing interests**

The author(s) declare that they have no competing interests.

**Authors’ contributions**

SR conceived of the study and participated in its design and data collection. AR participated in data collection, analysis and drafting of manuscript. DB participated in design and coordination of the study. All authors read and approved the final version of the manuscript.

**Acknowledgements**

Authors would like to thank Pratik Trivedi for his help toward the structuring of this manuscript.

**References**

1. Willmore JG, Shearman CH: *On the differential diagnosis of the dysenteries: the value of the cell exudate in the stools of acute amoebic and bacillary dysentery*. *Lancet* 1918, ii:200-206.
2. Harris JC, Dupont HL, Hornick RB: *Fecal leukocytes in diarrheal illness*. *Ann Intern Med* 1972, 76(5):697-703.
3. Kyne L, Hamel MB, Polavaram R, Kelly CP: Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. *Clin Infect Dis* 2002, 34(3):346-353.

4. Kyne L, Farrell RJ, Kelly CP: *Clostridium difficile*. *Gastroenterol Clin Nort Am* 2001, 30(3):737-777.

5. De Girolami PC, Hanff PA, Eichelberger K, Longhi L, Teresa H, Pratt J, Cheng A, Letourneau JM, Thorne GM: Multicenter evaluation of a new enzyme immunoassay for detection of *Clostridium difficile* enterotoxins. *J Clin Microbiol* 1992, 30(5):1085-1088.

6. Alsaie SS, Meyer P, Dryja D: Comparison of two commercially available enzyme immunoassays for detection of *Clostridium difficile* in stool specimens. *J Clin Microbiol* 1994, 32(1):51-53.

7. Massey V, Gregson DB, Chagla AH, Storey M, John MA, Hussain Z: Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of *Clostridium difficile* diarrhea. *Am J Clin Pathol* 2003, 119(1):45-49.

8. Huicho L, Sanchez D, Contreras M, Paredes M, Murga H, Chinchay L, Guevara G: Occult blood and fecal leukocytes as screening tests in childhood infectious diarrhea: an old problem revisited. *Pediatr Infect Dis J* 1993, 12(4):474-477.

9. Savola KL, Baron EJ, Tompkins LS, Passaro DJ: Fecal leukocyte stain has diagnostic value for outpatients but not inpatients. *J Clin Microbiol* 2001, 39(1):266-269.

10. Marx CE, Morris A, Wilson ML, Reller LB: Fecal leukocytes in stool specimens submitted for *Clostridium difficile* toxin assay. *Diagn Microbiol Infect Dis* 1993, 16(4):313-315.

11. Manabe YC, Vintz JM, Moore RD, Merz C, Charache P, Bartlett JG: *Clostridium difficile* colitis: an efficient clinical approach to diagnosis. *Ann Intern Med* 1995, 123(11):835-840.

12. Shankelzter CJ, Peterson LR, Olson MN, Gerdng DN: Prospective study of gram-stained stool smears in diagnosis of *Clostridium difficile* colitis. *J Clin Microbiol* 1983, 17(5):906-908.

13. Bartlett JG: How to identify the cause of antibiotic-associated diarrhea. *J Infect Illn* 1994, 9(12):1063-1067.

14. Fekety R, Shah AB: Diagnosis and treatment of *Clostridium difficile* colitis. *JAMA* 1983, 249(1):71-75.

15. Steiner TS, Flores CA, Pizarro TT, Guerrant RL: Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe *Clostridium difficile* colitis. *Clin Diagn Lab Immunol* 1997, 4(6):719-722.

16. Fine KD, Ogunji F, George J, Niehaus MD, Guerrant RL: Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. *Am J Gastroenterol* 1998, 93(8):1300-1305.

17. Huicho L, Garcia-Garcia Y, Uchima N, Zerpa R, Guerrant RL: Fecal lactoferrin, fecal leukocytes and occult blood in the diagnostic approach to childhood invasive diarrhea. *Pediatr Infect Dis J* 1997, 16(7):644-647.

18. Huicho L, Campos M, Rivera J, Guerrant RL: Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview. *Pediatr Infect Dis J* 1996, 15(6):486-494.

19. Brouwer J: Semiquantitative determination of fecal leukocyte esterase by a dip-and-read assay. *Clin Chem* 1993, 39(12):2531-2532.